Stocktoria
MACROGENICS INC MGNX
MACROGENICS INC (MGNX) earns a Piotroski F-score of 2/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $149.5M at a -49.9% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -0.6 — elevated (above the −1.78 line — aggressive-accounting signals worth a closer look) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 2/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.688 |
| Retained earnings / assets | -4.845 |
| EBIT / assets | -0.284 |
| Equity / liabilities | 0.276 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| MGNX | MACROGENICS INC | 2/9 | -12.89 | — | -0.3% |
| ELTP | ELITE PHARMACEUTICALS INC /NV/ | 6/9 | 7.73 | 9.5 | +77.1% |
| KPTI | Karyopharm Therapeutics Inc. | 2/9 | — | — | +0.6% |
| HRTX | HERON THERAPEUTICS, INC. /DE/ | 2/9 | — | — | +7.4% |
| LQDA | Liquidia Corp | 3/9 | -4.36 | — | +1031.2% |
| LFCR | LIFECORE BIOMEDICAL, INC. \DE\ | 3/9 | -1.75 | — | +0.5% |
| SNDX | Syndax Pharmaceuticals Inc | 1/9 | -7.54 | — | +627.8% |
About MACROGENICS INC
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.
FAQ
Is MGNX financially healthy?
MACROGENICS INC's Piotroski F-score is 2/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does MGNX pay a dividend?
No, MACROGENICS INC does not currently pay a dividend.
How profitable is MGNX?
In FY2025, MACROGENICS INC had a net margin of -49.9% and a return on equity of -134.2%.
What is the analyst price target for MGNX?
The average Wall-Street price target for MACROGENICS INC is $6.75, about 67.9% above the recent price, from 4 analysts.
Is MGNX a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on MACROGENICS INC: a Piotroski F-score of 2/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.